All Title Author
Keywords Abstract

PADI4 Haplotypes in Association with RA Mexican Patients, a New Prospect for Antigen Modulation

DOI: 10.1155/2013/383681

Full-Text   Cite this paper   Add to My Lib


Peptidyl arginine deiminase IV (PAD 4) is the responsible enzyme for a posttranslational modification called citrullination, originating the antigenic determinant recognized by anti-cyclic citrullinated peptide antibodies (ACPA). Four SNPs (single nucleotide polymorphisms) have been described in PADI4 gene to form a susceptibility haplotype for rheumatoid arthritis (RA); nevertheless, results in association studies appear contradictory in different populations. The aim of the study was to analyze if the presence of three SNPs in PADI4 gene susceptibility haplotype (GTG) is associated with ACPA positivity in patients with RA. This was a cross-sectional study that included 86 RA patients and 98 healthy controls. Polymorphisms PADI4_89, PADI4_90, and PADI4_92 in the PADI4 gene were genotyped. The susceptibility haplotype (GTG) was more frequent in RA patients; interestingly, we found a new haplotype associated with RA with a higher frequency (GTC). There were no associations between polymorphisms and high scores in Spanish HAQ-DI and DAS-28, but we did find an association between RARBIS index and PADI4_89, PADI4_90 polymorphisms. We could not confirm an association between susceptibility haplotype presence and ACPA positivity. Further evidence about proteomic expression of this gene will determine its participation in antigenic generation and autoimmunity. 1. Introduction Rheumatoid arthritis (RA) is an autoimmune disease, characterized by articular inflammation which can lead to joint destruction. RA prevalence is 1% worldwide with considerable variation between ethnic groups, with a higher prevalence in Caucasians compared with Asiatic populations [1, 2]. This disease is more frequent in females (3?:?1) around the fourth decade [3]; some studies suggest that sexual hormones, specifically estrogens, can cause hyperactivity in B and T cell functions [4]. RA represents a disease with risk of function disability due to articular damage as a result of ongoing inflammation, which is irretrievable. In order to limit illness incapability, it is necessary to establish the diagnostic as soon as possible and treat the condition. Genetic predisposition for this disease is supported by the following findings: first degree relatives of patients with RA have a four to six times greater risk to develop the disease [5]; presence of some HLA-DR molecules (HLA-DRB1*0401 and HLA-DRB1*0404) are genetic factors commonly found in RA, and its presence is associated with a more severe disease [6, 7]. The epidemiological genetic information suggests that the heritability for this


[1]  A. M. Abdel-Nasser, J. J. Rasker, and H. A. Valkenburg, “Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis,” Seminars in Arthritis and Rheumatism, vol. 27, no. 2, pp. 123–140, 1997.
[2]  Y. Alamanos and A. A. Drosos, “Epidemiology of adult rheumatoid arthritis,” Autoimmunity Reviews, vol. 4, no. 3, pp. 130–136, 2005.
[3]  G. S. Firestein, “Evolving concepts of rheumatoid arthritis,” Nature, vol. 423, no. 6937, pp. 356–361, 2003.
[4]  S. A. Ahmed, B. D. Hissong, D. Verthelyi, K. Donner, K. Becker, and E. Karpuzoglu-Sahin, “Gender and risk of autoimmune diseases: possible role of estrogenic compounds,” Environmental Health Perspectives, vol. 107, supplement 5, pp. 681–686, 1999.
[5]  R. M. Nakamura, “Progress in the use of biochemical and biological markers for evaluation of rheumatoid arthritis,” Journal of Clinical Laboratory Analysis, vol. 14, no. 6, pp. 305–313, 2000.
[6]  D. L. Mattey, W. Thomson, W. E. R. Ollier et al., “Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study,” Arthritis and Rheumatism, vol. 56, no. 5, pp. 1408–1416, 2007.
[7]  F. A. van Gaalen, J. van Aken, T. W. J. Huizinga et al., “Association between HLA class II genes and autoantibodies to Cyclic Citrullinated Peptides (CCPs) influences the severity of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 50, no. 7, pp. 2113–2121, 2004.
[8]  C. M. Deighton, D. J. Walker, I. D. Griffiths, and D. F. Roberts, “The contribution of HLA to rheumatoid arthritis,” Clinical Genetics, vol. 36, no. 3, pp. 178–182, 1989.
[9]  A. Suzuki, R. Yamada, X. Chang et al., “Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis,” Nature Genetics, vol. 34, no. 4, pp. 395–402, 2003.
[10]  E. R. Vossenaar, T. J. M. Smeets, M. C. Kraan, J. M. Raats, W. J. van Venrooij, and P. P. Tak, “The presence of citrullinated proteins is not specific for rheumatoid synovial tissue,” Arthritis and Rheumatism, vol. 50, no. 11, pp. 3485–3494, 2004.
[11]  B. Hoppe, T. Haupl, R. Gruber et al., “Detailed analysis of the variability of peptidylarginine deiminase type 4 in German patients with rheumatoid arthritis: a case-control study,” Arthritis Research & Therapy, vol. 8, no. 2, article R34, 2006.
[12]  S. M. J. Harney, C. Meisel, A.-M. Sims, P. Y. Woon, B. P. Wordsworth, and M. A. Brown, “Genetic and genomic studies of PADI4 in rheumatoid arthritis,” Rheumatology, vol. 44, no. 7, pp. 869–872, 2005.
[13]  Y. Luo, K. Arita, M. Bhatia et al., “Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization,” Biochemistry, vol. 45, no. 39, pp. 11727–11736, 2006.
[14]  K. Nakashima, T. Hagiwara, and M. Yamada, “Nuclear localization of peptidylarginine deiminase V and histone deimination in granulocytes,” Journal of Biological Chemistry, vol. 277, no. 51, pp. 49562–49568, 2002.
[15]  T. Senshu, S. Kan, H. Ogawa, M. Manabe, and H. Asaga, “Preferential deimination of keratin K1 and filaggrin during the terminal differentiation of human epidermis,” Biochemical and Biophysical Research Communications, vol. 225, no. 3, pp. 712–719, 1996.
[16]  L. B. Pritzker, T. A. Nguyen, and M. A. Moscarello, “The developmental expression and activity of peptidylarginine deiminase in the mouse,” Neuroscience Letters, vol. 266, no. 3, pp. 161–164, 1999.
[17]  Y. Wang, M. Li, S. Stadler et al., “Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation,” Journal of Cell Biology, vol. 184, no. 2, pp. 205–213, 2009.
[18]  R. S. Lewis, “Calcium signaling mechanisms in T lymphocytes,” Annual Review of Immunology, vol. 19, pp. 497–521, 2001.
[19]  M. E. Stensland, S. Pollmann, ?. Molberg, L. M. Sollid, and B. Fleckenstein, “Primary sequence, together with other factors, influence peptide deimination by peptidylarginine deiminase-4,” Biological Chemistry, vol. 390, no. 2, pp. 99–107, 2009.
[20]  E. R. Vossenaar, T. R. D. Radstake, A. van der Heijden et al., “Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages,” Annals of the Rheumatic Diseases, vol. 63, no. 4, pp. 373–381, 2004.
[21]  L. Klareskog, M. Widhe, M. Hermansson, and J. Ronnelid, “Antibodies to citrullinated proteins in arthritis: pathology and promise,” Current Opinion in Rheumatology, vol. 20, no. 3, pp. 300–305, 2008.
[22]  S. Rantap??-Dahlqvist, B. A. W. de Jong, E. Berglin et al., “Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 48, no. 10, pp. 2741–2749, 2003.
[23]  M. M. J. Nielen, D. van Schaardenburg, H. W. Reesink et al., “Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors,” Arthritis and Rheumatism, vol. 50, no. 2, pp. 380–386, 2004.
[24]  F. A. van Gaalen, S. P. Linn-Rasker, W. J. van Venrooij et al., “Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study,” Arthritis and Rheumatism, vol. 50, no. 3, pp. 709–715, 2004.
[25]  A. Kastbom, G. Strandberg, A. Lindroos, and T. Skogh, “Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project),” Annals of the Rheumatic Diseases, vol. 63, no. 9, pp. 1085–1089, 2004.
[26]  K. Ikari, M. Kuwahara, T. Nakamura et al., “Association between PADI4 and rheumatoid arthritis: a replication study,” Arthritis and Rheumatism, vol. 52, no. 10, pp. 3054–3057, 2005.
[27]  A. Barton, J. Bowes, S. Eyre et al., “A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population,” Arthritis and Rheumatism, vol. 50, no. 4, pp. 1117–1121, 2004.
[28]  L. Caponi, E. Petit-Teixeira, M. Sebbag et al., “A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population,” Annals of the Rheumatic Diseases, vol. 64, no. 4, pp. 587–593, 2005.
[29]  A. Martinez, A. Valdivia, D. Pascual-Salcedo et al., “PADI4 polymorphisms are not associated with rheumatoid arthritis in the Spanish population,” Rheumatology, vol. 44, no. 10, pp. 1263–1266, 2005.
[30]  F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., “The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 31, no. 3, pp. 315–324, 1988.
[31]  M. L. L. Prevoo, M. A. van'T Hof, H. H. Kuper, M. A. van Leeuwen, L. B. A. van de Putte, and P. L. C. M. van Riel, “Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 38, no. 1, pp. 44–48, 1995.
[32]  M. H. Cardiel, M. Abello-Banfi, R. Ruiz-Mercado, and D. Alarcon-Segovia, “How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI),” Clinical and Experimental Rheumatology, vol. 11, no. 2, pp. 117–121, 1993.
[33]  G. Ting, S. Schneeweiss, J. N. Katz et al., “Performance of a rheumatoid arthritis records-based index of severity,” Journal of Rheumatology, vol. 32, no. 9, pp. 1679–1687, 2005.
[34]  S. Gustincich, G. Manfioletti, G. Del Sal, C. Schneider, and P. Carninci, “A fast method for high-quality genomic DNA extraction from whole human blood,” BioTechniques, vol. 11, no. 3, pp. 298–302, 1991.
[35]  M. Stephens, N. J. Smith, and P. Donnelly, “A new statistical method for haplotype reconstruction from population data,” American Journal of Human Genetics, vol. 68, pp. 978–989, 2001.
[36]  A. K. Abbas and A. H. Lichtman, Basic Immunology: Functions and Disorders of the Immune System, WB Saunders, Philadelphia, Pa, USA, 2nd edition, 2004.
[37]  P. Matzinger, “The danger model: a renewed sense of self,” Science, vol. 296, no. 5566, pp. 301–305, 2002.
[38]  K. L. Rock and H. Kono, “The inflammatory response to cell death,” Annual Review of Pathology, vol. 3, pp. 99–126, 2008.
[39]  H. Kono and K. L. Rock, “How dying cells alert the immune system to danger,” Nature Reviews Immunology, vol. 8, no. 4, pp. 279–289, 2008.
[40]  F. Martinon, K. Burns, and J. Tschopp, “The Inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β,” Molecular Cell, vol. 10, no. 2, pp. 417–426, 2002.
[41]  F. Martinon, A. Mayor, and J. Tschopp, “The inflammasomes: guardians of the body,” Annual Review of Immunology, vol. 27, pp. 229–265, 2009.
[42]  C. M. Weyand and J. J. Goronzy, “Pathogenesis of rheumatoid arthritis,” Medical Clinics of North America, vol. 81, no. 1, pp. 29–55, 1997.
[43]  T. Iwamoto, K. Ikari, T. Nakamura et al., “Association between PADI4 and rheumatoid arthritis: a meta-analysis,” Rheumatology, vol. 45, no. 7, pp. 804–807, 2006.
[44]  Y. H. Lee, Y. H. Rho, S. J. Choi, J. D. Ji, and G. G. Song, “PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis,” Rheumatology International, vol. 27, no. 9, pp. 827–833, 2007.
[45]  C. Gorodezky, C. Alaez, M. N. Vázquez-García et al., “The genetic structure of Mexican Mestizos of different locations: tracking back their origins through MHC genes, blood group systems, and microsatellites,” Human Immunology, vol. 62, no. 9, pp. 979–991, 2001.
[46]  B. Hoppe, G. A. Heymann, F. Tolou, H. Kiesewetter, T. Doerner, and A. Salama, “High variability of peptidylarginine deiminase 4 (PADI4) in a healthy white population: characterization of six new variants of PADI4 exons 2-4 by a novel haplotype-specific sequencing-based approach,” Journal of Molecular Medicine, vol. 82, no. 11, pp. 762–767, 2004.
[47]  C. P. Kang, H.-S. Lee, H. Ju, H. Cho, C. Kang, and S.-C. Bae, “A functional haplotype of the PADI4 gene associated with increased rheumatoid arthritis susceptibility in Koreans,” Arthritis and Rheumatism, vol. 54, no. 1, pp. 90–96, 2006.
[48]  F. Gandjbakhch, I. Fajardy, B. Ferré et al., “A functional haplotype of PADI4 gene in rheumatoid arthritis: positive correlation in a french population,” Journal of Rheumatology, vol. 36, no. 5, pp. 881–886, 2009.
[49]  G. A. Schellekens, H. Visser, B. A. de Jong et al., “The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide,” Arthritis and Rheumatism, vol. 43, no. 1, pp. 155–163, 2000.
[50]  M. G. Zavala-Cerna, A. Nava, E. Garcia-Castaneda, J. Duran-Gonzalez, M. J. Arias-Merino, and M. Salazar-Paramo, “Serum IgG activity against cyclic citrullinated peptide in patients evaluated for rheumatoid factor correlates with the IgM isotype,” Rheumatology International, vol. 28, no. 9, pp. 851–857, 2008.
[51]  G. Lakos, L. Soos, A. Fekete et al., “Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope,” Clinical and Experimental Rheumatology, vol. 26, no. 2, pp. 253–260, 2008.
[52]  K. N. Verpoort, C. M. Jol-van der Zijde, E. A. M. Papendrecht-van der Voort et al., “Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response,” Arthritis and Rheumatism, vol. 54, no. 12, pp. 3799–3808, 2006.
[53]  D. Makrygiannakis, E. Af Klint, I. E. Lundberg et al., “Citrullination is an inflammation-dependent process,” Annals of the Rheumatic Diseases, vol. 65, no. 9, pp. 1219–1222, 2006.
[54]  J. A. Hill, S. Southwood, A. Sette, A. M. Jevnikar, D. A. Bell, and E. Cairns, “Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule,” Journal of Immunology, vol. 171, no. 2, pp. 538–541, 2003.
[55]  R. M. Plenge, L. Padyukov, E. F. Remmers et al., “Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4,” American Journal of Human Genetics, vol. 77, no. 6, pp. 1044–1060, 2005.


comments powered by Disqus